GenSight Sees Positives In Pivotal RESCUE Trial, Despite Missing Primary Endpoint
Executive Summary
The company's gene therapy didn't hit the primary endpoints in either of its two Phase III studies in a severe genetic retinal disease reported so far, but a third trial designed through a special protocol assessment with the US FDA is ongoing.